title: Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
authors.affiliation: Royal National Hospital for Rheumatic Diseases, Upper Borough Wells, Bath, BA1 IRL, UK.
authors.forename: S
authors.initials: S
authors.lastname: Kyle
authors.forename: D
authors.initials: D
authors.lastname: Chandler
authors.forename: C E M
authors.initials: CE
authors.lastname: Griffiths
authors.forename: P
authors.initials: P
authors.lastname: Helliwell
authors.forename: J
authors.initials: J
authors.lastname: Lewis
authors.forename: I
authors.initials: I
authors.lastname: McInnes
authors.forename: S
authors.initials: S
authors.lastname: Oliver
authors.forename: D
authors.initials: D
authors.lastname: Symmons
authors.forename: N
authors.initials: N
authors.lastname: McHugh
mesh_terms: D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D012460:Sulfasalazine; D000069285:Infliximab; D000077339:Leflunomide; D000068800:Etanercept